Outcome of oncological patients admitted with COVID-19: experience of a hospital center in northern Italy.
COVID-19
SARS-CoV-2
cancer
chemotherapy
immunodeficiency
Journal
Therapeutic advances in medical oncology
ISSN: 1758-8340
Titre abrégé: Ther Adv Med Oncol
Pays: England
ID NLM: 101510808
Informations de publication
Date de publication:
2020
2020
Historique:
received:
16
06
2020
accepted:
04
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
17
10
2020
Statut:
epublish
Résumé
Recent literature regarding the outcome of cancer patients infected with COVID-19 are not encouraging. Nevertheless, current evidence on the risk and benefits of continuing oncological treatment of cancer patients during the pandemic remains insufficient. We provide our experience in a center with high access for patients with COVID-19-associated pneumonia in Lombardy, Italy. We conducted a retrospective study using a prospectively maintained database of patients admitted to our hospital between 25 February 2020 and 9 April 2020 with a confirmed diagnosis of COVID-19 pneumonia. A total of 53 patients with a history or current oncological disease were included in this study. Sixteen oncological patients (30.2%) died during hospitalization. Multivariable logistic regression analysis found that age (Odds ratio [OR]: 1.17, The presence of active oncological disease is independently related to mortality as well as age and diabetes. The majority of patients who died were frail. Careful evaluation of the risks and benefits of treatment in frail patients is needed, considering that difficult access to intensive care may have affected the mortality rate.
Sections du résumé
BACKGROUND
BACKGROUND
Recent literature regarding the outcome of cancer patients infected with COVID-19 are not encouraging. Nevertheless, current evidence on the risk and benefits of continuing oncological treatment of cancer patients during the pandemic remains insufficient. We provide our experience in a center with high access for patients with COVID-19-associated pneumonia in Lombardy, Italy. We conducted a retrospective study using a prospectively maintained database of patients admitted to our hospital between 25 February 2020 and 9 April 2020 with a confirmed diagnosis of COVID-19 pneumonia.
RESULTS
RESULTS
A total of 53 patients with a history or current oncological disease were included in this study. Sixteen oncological patients (30.2%) died during hospitalization. Multivariable logistic regression analysis found that age (Odds ratio [OR]: 1.17,
CONCLUSION
CONCLUSIONS
The presence of active oncological disease is independently related to mortality as well as age and diabetes. The majority of patients who died were frail. Careful evaluation of the risks and benefits of treatment in frail patients is needed, considering that difficult access to intensive care may have affected the mortality rate.
Identifiants
pubmed: 33062065
doi: 10.1177/1758835920962370
pii: 10.1177_1758835920962370
pmc: PMC7533930
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1758835920962370Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: Each author certifies that he or she, or a member of his or her immediate family, has no funding or commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangements, etc.) that might pose a conflict of interest in connection with the submitted article.
Références
Am J Epidemiol. 2007 Mar 15;165(6):710-8
pubmed: 17182981
Blood. 1994 Oct 1;84(7):2221-8
pubmed: 7919339
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
Int Arch Allergy Immunol. 2020;181(6):467-475
pubmed: 32392562
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
JCO Oncol Pract. 2020 Aug;16(8):467-482
pubmed: 32401686
Eur Respir J. 2020 Jun 11;55(6):
pubmed: 32398296
J Infect. 2020 Jul;81(1):e61-e66
pubmed: 32335173
Eur Heart J. 2020 May 14;41(19):1821-1829
pubmed: 32383763
Lancet Respir Med. 2020 May;8(5):506-517
pubmed: 32272080
Lancet Oncol. 2020 May;21(5):e236
pubmed: 32302533
Ann Oncol. 2020 Aug;31(8):1088-1089
pubmed: 32330541
Curr Probl Cardiol. 2020 Aug;45(8):100617
pubmed: 32402515
Lancet Oncol. 2020 Apr;21(4):e181
pubmed: 32142621
J Med Virol. 2020 Apr;92(4):401-402
pubmed: 31950516
Lancet Respir Med. 2020 May;8(5):430-432
pubmed: 32272081
Lancet Rheumatol. 2020 Jul;2(7):e437-e445
pubmed: 32835247
Int J Surg. 2020 Apr;76:71-76
pubmed: 32112977
Liver Transpl. 2020 Jun;26(6):832-834
pubmed: 32196933
Eur J Cancer. 2020 Jun;132:199-206
pubmed: 32380430
J Geriatr Oncol. 2020 Sep;11(7):1175-1181
pubmed: 32402764
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Cancer Cell Int. 2020 Jan 10;20:15
pubmed: 31938023
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
J Diabetes Sci Technol. 2020 Jul;14(4):813-821
pubmed: 32389027